Malignant Meningioma Cell Lines

IOMM-Lee and HKBMM, human malignant meningioma cell lines, were obtained from the American Type Culture Collection (Manassas, VA, USA) and from the Riken BioResource Center (Tsukuba, Japan), respectively. Their characteristics as malignant meningioma cells were confirmed in a previous study [8 (link)]. IOMM-Lee cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). HKBMM cells were cultured in Ham’s F12 medium supplemented with 10% FBS.

Free full text: Click here

Yamamoto M., Suzuki S., Togashi K., Sugai A., Okada M, & Kitanaka C. (2022). Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Cancers, 14(7), 1706.

Publication 2022

IOMM-Lee HKBMM

Cell lines Cells Cultured medium Eagle Fetal bovine serum Human Malignant meningioma

Corresponding Organization : Yamagata University

Top 5 similar protocols

Variable analysis

independent variables

Cell line type (IOMM-Lee and HKBMM)

dependent variables

Characteristics as malignant meningioma cells

control variables

Culture medium (DMEM for IOMM-Lee cells, Ham's F12 for HKBMM cells)
Fetal bovine serum (10% FBS for both cell lines)

controls

No positive or negative controls were explicitly mentioned.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!